Effects of GLP-1 analogue in multiple sclerosis

Ki vehet részt

• Main inclusion criteria • Must freely consent to participate in this trial and personally sign the informed consent prior to performing any procedure in this study. • Male or female aged 18 to 60 years (inclusive) at the time of the first visit to this study. • Able to understand the requirements and follow the procedures within this study. • Patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis, with a worse prognosis due to higher disease activity, with a disease duration of at least 1 year • EDSS<5, • Set on stable treatment of the underlying disease for at least three (3) months

Ki nem vehet részt

• Main • diabetes mellitus on diet, oral antidiabetic drugs or insulin • other serious chronic diseases • Acute pancreatitiswith a historyof • oncological diseases • long-term use of medications such as glucocorticoids, Antidepressants • Severe renal impairment and kidney disease in the last stage. • Severe hepatic impairment. • Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transit ischemic attack in 90 days before the dateof screening. • New Class IV congestive heart failure York Heart Association (NYHA). • Historyof major surgical procedures involving the stomach or smallintestine potentially affecting the absorption of medicinal products and/or nutrients, as assessed by the • Pregnancy • breastfeeding • Drug use or alcoholuse • the presence of metal components in the body • Known hypersensitivity to the investigational drug, excipients or hypersensitivity to a drug with a similar structure